Aspira Pathlab & Diagnostics Ltd

Jay Arvind Bhanushali has acquired 1,387 equity shares, representing 0.01% of the total share capital, in Aspira Pathlab & Diagnostics Ltd. This acquisition, made through the open market between September 11-16, 2026, increases his total holding to 7,47,838 shares, or 7.27% of the company's equity. The transaction occurred amidst a total equity share capital of Rs. 10,29,30,000 divided into 1,02,93,000 equity shares of Rs. 10 each.

Aspira Pathlab & Diagnostics Ltd announced its Board of Directors has approved a Rights Issue to raise up to ₹65 crore. The funds will be raised through equity or convertible instruments, subject to shareholder and regulatory approvals. A dedicated Rights Issue Committee has been formed to manage the process, including determining the record date, issue price, entitlement ratio, and appointing intermediaries. The meeting where these decisions were made took place on September 12, 2026.

Aspira Pathlab & Diagnostics Ltd announced its Board of Directors has approved a proposal to raise up to ₹65 crore through a Rights Issue. The funds will be raised from eligible equity shareholders, with the exact terms like issue price and ratio to be decided by a newly constituted Rights Issue Committee. This committee will also determine the record date and appoint necessary intermediaries. The Rights Issue, which can be in the form of equity or convertible instruments, is subject to shareholder and regulatory approvals.

Aspira Pathlab & Diagnostics Ltd announced that its Board of Directors, in a meeting held on September 12, 2026, approved a proposal to raise funds not exceeding ₹65 crore through a Rights Issue. The issue will be offered to eligible equity shareholders as of a to-be-notified record date. The rights issue may involve equity or other convertible instruments. A dedicated Rights Issue Committee has been constituted to manage the process, including setting the issue price, entitlement ratio, and appointing intermediaries. The meeting concluded within 30 minutes.

Jay Arvind Bhanushali has disclosed an increase in his shareholding in Aspira Pathlab & Diagnostics Ltd. The acquisition involved 74 equity shares, bringing his total holding to 746,451 shares, representing 7.25% of the total equity share capital. The transaction occurred on September 10, 2026, via the open market. This disclosure is made in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aspira Pathlab & Diagnostics Ltd has announced a Board of Directors meeting scheduled for September 12, 2026. The primary agenda item is to consider and approve a proposal for raising funds. This could involve issuing various instruments such as equity shares, warrants convertible into equity shares, through methods like preferential issue, private placements, rights issue, or other permitted means, subject to necessary approvals. The meeting will also address other incidental matters.

Jay Arvind Bhanushali has acquired 623 equity shares, representing 0.0060% of the total share capital, in Aspira Pathlab & Diagnostics Ltd. This disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Following this acquisition, Mr. Bhanushali's total holding in the company stands at 7,46,377 equity shares. The transaction details indicate a value of Rs. 10,29,30,000 divided into 1,02,93,000 equity shares of Rs. 10 each, with the acquisition date noted as September 2, 2026.

Jay Arvind Bhanushali has acquired 957 equity shares, representing 0.0092% of the total share capital, in Aspira Pathlab & Diagnostics Ltd. This disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Following this acquisition, Mr. Bhanushali's total holding in the company has increased to 7,45,754 equity shares, which constitutes 7.24% of the total share capital.

Aspira Pathlab & Diagnostics Ltd has dispatched letters containing the weblink for its Annual Report for the Financial Year 2025-26. This communication is directed to members who have not registered their email addresses. The report details are accessible via www.aspiradiagnostics.com, with the specific path being https://www.aspiradiagnostics.com/investor-relation/. The company also announced its 53rd Annual General Meeting (AGM) scheduled for September 25, 2026, to be held via Video Conferencing. Members are encouraged to update their email addresses for future communications and to support green initiatives. Contact details for the Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited, are provided for queries.

Aspira Pathlab & Diagnostics Ltd has issued a notice regarding its 53rd Annual General Meeting (AGM) and has enclosed the Annual Report for the financial year 2025-26. The report includes audited financial statements for the year ended March 31, 2026, the Board's Report, and the Auditors' Report. This information is being disseminated to shareholders via email and is also available on the company's website. The filing complies with SEBI and MCA regulations.